Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
2(40.0%)
Phase 2
2(40.0%)
Phase 1
1(20.0%)
5Total
Phase 3(2)
Phase 2(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06633783Phase 3Not Yet Recruiting

A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®

Role: lead

NCT05816057Phase 3Completed

A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus

Role: lead

NCT01918241Phase 2Unknown

Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia

Role: lead

NCT01637493Phase 1Unknown

Pharmacokinetics and Pharmacodynamics Study of Pegfilgrastim in Chemotherapy Patients

Role: lead

NCT00503386Phase 2Completed

Safety and Efficacy of Palonosetron in Preventing Chemotherapy-induced Nausea and Vomiting

Role: lead

All 5 trials loaded